The KEYNOTE-716 study evaluated the safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma. A recent analysis from the trial was published by Luke et al in the Journal of Clinical Oncology.
Question 1 of 5
What was the primary endpoint of the KEYNOTE-716 study?
